MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma

Authors: Lucia Y. Chen, Santiago Thibaud, Saoirse Bodnar, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J. Sanchez, Cesar Rodriguez, Adriana C. Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath

Source: Blood Advances, Vol 9, Iss 1, Pp 176-179 (2025)

Subject Terms: Specialties of internal medicine, RC581-951

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2473952924006578; https://doaj.org/toc/2473-9529

Access URL: https://doaj.org/article/70f0599c68a448cb8730e39b768fd3ab

Bispecific antibodies in the treatment of multiple myeloma

Authors: Anup Joseph Devasia, Ajai Chari, Guido Lancman

Source: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-17 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/0b22487062fd433e911b0bd050f23132

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Authors: Ajai Chari, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson

Source: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/bb6796db0ba84a22b84787f34a884f56

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Authors: Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob Laubach, Timothy M. Schmidt, Douglas W. Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Bhagirathbhai R. Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees

Source: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/ebc38d6b2c3c4c4a957f6410c2bc2f56

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Authors: Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari

Source: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-13 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/3ef6305f5c894c229cdfe5cd8505447b

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

Authors: Seunghee Kim-Schulze, Sundar Jagannath, Sacha Gnjatic, Ajai Chari, Samir Parekh, Keren Osman, Selma Bekri, Hearn Jay Cho, David G Coffey, Adolfo Aleman, Simone Kats, Amishi Dhadwal, Donna Catamero

Source: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/12/4/e008110.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/4790a00a661e458ba2ebf32b8bdaa81f

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Authors: Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria-Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosiñol, Stefano Tarantolo, Howard Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt

Source: Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/8ddf4818d05d49919016d3e65c55a1f9

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple MyelomaResearch in context

Authors: Adolfo Aleman, Morgan van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Christian Cognigni, Jacob Mischka, Lucia Y. Chen, Bhaskar Upadhyaya, Kseniya Serebryakova, Jessica R. Nardulli, Neko Lyttle, Katerina Kappes, Hayley Jackson, Charles R. Gleason, Annika Oostenink, Gianna Y. Cai, Oliver Van Oekelen, Harm van Bakel, Emilia Mia Sordillo, Carlos Cordon-Cardo, Miriam Merad, Sundar Jagannath, Ania Wajnberg, Viviana Simon, Samir Parekh, Hala Alshammary, Dalles Andre, Radhika Banu, Katherine Beach, María Carolina Bermúdez-González, Ajai Chari, Yuexing Chen, Hearn Cho, Adolfo Firpo, Ana Silvia Gonzalez-Reiche, Eun Hye Kim, Giulio Kleiner, Florian Krammer, Jacob Mauldin, Rao Mendu, Brian Monahan, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adrianna Rossi, Ashley Salimbangon, Laryssa Sanchez, Daniel Verina

Source: EBioMedicine, Vol 98, Iss , Pp 104886- (2023)

Subject Terms: COVID-19, Bivalent vaccine, Multiple Myeloma, SARS-CoV-2, Omicron, Hematological malignancy, Medicine, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352396423004528; https://doaj.org/toc/2352-3964

Access URL: https://doaj.org/article/cc58fda45a4f4326af1b2763e037bc22

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant

Authors: Sikander Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, Dasha Cherepanov, Bridgette Kanz Schroader, Dorothy Romanus, Eileen Farrelly, Ajai Chari

Source: Cancer Medicine, Vol 12, Iss 3, Pp 3145-3159 (2023)

Subject Terms: chemotherapy, clinical management, multiple myeloma, target therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/0312cf2755424ff7996a082a257356af

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2

Authors: Lien Vandenberk, Paula Rodríguez-Otero, Maria-Victoria Mateos, Ajai Chari, Bhagirathbhai Dholaria, Deeksha Vishwamitra, Sheri Skerget, M Damiette Smit, Kalpana Bakshi, Sangmin Lee, Nizar Bahlis, Niels WCJ van de Donk, Raluca Verona

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/dbff19d26aaa4728b508224666963930

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Authors: Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari

Source: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-1 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/e057160cc1394d3d997f011a0b01b171

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS

Authors: Nizar J Bahlis, Katja Weisel, Maria-Victoria Mateos, Hartmut Goldschmidt, Tom Martin, Daniel Morillo, Donna Reece, Paula Rodríguez-Otero, Manisha Bhutani, Anita D’souza, Albert Oriol, Laura Rosiñol Dachs, Bhagirathbhai Dholaria, Kalpana Bakshi, Lijuan Kang, Lien Vandenberk, Damiette Smit, Ralph Wäsch, Niels W.C.J. van de Donk, Ajai Chari

Source: HemaSphere, Vol 7, p e90062ca (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000967680.90062.ca; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/2bcd2dcc8c5c44adb5296cd4eb1544f2

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

Authors: Manisha Bhutani, Alfred Garfall, Katarina Uttervall, Saad Z Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, Ajai Chari

Source: HemaSphere, Vol 7, p e90600b0 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000970428.90600.b0; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/57fb171e99b34443b7272faba575de36

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Authors: Ajai Chari, Joris Diels, Suzy Van Sanden, Lixia Pei, Eric Ammann, Christoph Heuck, Colleen Kane, Anil Londhe, Steve Peterson, Donna Reece

Source: HemaSphere, Vol 7, p e81043cc (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000970456.81043.cc; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/e73487272c36480c809ab1d01fbc725f

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Authors: Cyrille Touzeau, Carolina Schinke, Monique Minnema, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, Maria-Victoria Mateos, Leo Rasche, Jing Christine Ye, Deeksha Vishwamitra, Xuewen MA, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna Goldberg, Christoph Heuck, Ajai Chari

Source: HemaSphere, Vol 7, p e5955094 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000967676.59550.94; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/210ee6a6b6b3433f9f01f65c5a97addf

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1

Authors: Leo Rasche, Carolina Schinke, Ajai Chari, Brea C. Lipe, Noa Lavi, Paula Rodríguez-Otero, Deeksha Vishwamitra, Sheri Skerget, Raluca Verona, Xuewen MA, Sheetal Khedkar, Brandi Hilder, Tara Masterson, Michela Campagna, Thomas Renaud, Jaszianne Tolbert, Christoph Heuck, Damiette Smit, Niels W.C.J. van de Donk

Source: HemaSphere, Vol 7, p e646904e (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000970472.64690.4e; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/9603217f9c9c4d2484865321c672794e

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Authors: Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter Voorhees

Source: Blood Cancer Journal, Vol 12, Iss 4, Pp 1-5 (2022)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/b428bc1646cf491fb069adf05f112f10

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Authors: Amrita Krishnan, Ajay K Nooka, Ajai Chari, Alfred L Garfall, Thomas G Martin, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Saad Z Usmani

Source: Journal of Comparative Effectiveness Research, Vol 12, Iss 6 (2023)

Subject Terms: b-cell maturation antigen, bispecific antibody, comparative effectiveness, indirect treatment comparison, majestec-1, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: https://doaj.org/toc/2042-6313

Access URL: https://doaj.org/article/d2234f01c82748d787b0b8d1a00b2e7e

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

Authors: Darren Pan, Jonathan L. Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Robert F. Cornell, Jeffrey A. Zonder, Joseph W. Fay, Manuel R. Modiano, Erin L. Moshier, Selena A. Rush, Brian J. Tunquist, Ajai Chari

Source: Cancer Medicine, Vol 11, Iss 2, Pp 358-370 (2022)

Subject Terms: chemotherapy, clinical cancer research, clinical trials, experimental, medical oncology, multiple myeloma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/8ceaef0a12fe48ab866e9efb57eded0b

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Authors: Evangelos Terpos, Joseph Mikhael, Roman Hajek, Ajai Chari, Sonja Zweegman, Hans C. Lee, María-Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gordon Cook, Katja C. Weisel, Caitlin L. Costello, Jennifer Elliott, Antonio Palumbo, Saad Z. Usmani

Source: Blood Cancer Journal, Vol 11, Iss 2, Pp 1-13 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/2fce7cb5103c4985b99805727b7b90b8